Disclosures: Full time employee of Abbott Vascular. Dra. Moreira Rebeca.SOLACI México Congress 2012. Find more presentations on the web site: www.solaci.org/

1. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
1
BVS for BTK
Rebecca Moreira
Director, R&D
Abbot Vascular
Santa Clara, CA
August 8, 2012

2. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
2
DISCLOSURES:
Full-time Employee
of Abbott Vascular

3. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
3
Device Study Lesions n Outcome
Igaki-Tamai
Igaki-Tamai FIM coronary 50 18% restenosis @ 12-months
PERSEUS SFA 45 50% restenosis @ 6-months
AMS
PROGRESS AMS coronary 63 48% restenosis @ 12-months
BEST BTK infrapopliteal 20 90% “clinical patency” @ 3-months
AMS INSIGHT infrapopliteal 117 68% restenosis @ 6-months
BIOSOLVE-I coronary 46 4.7% TLR @ 12-months
REVA
RESORB coronary 30 67% TLR @ 6-months
RESTORE coronary 26 Follow-up ongoing
Absorb
ABSORB
Cohort B*
coronary 101
2.0% TLR @ 6-months
4.0% TLR @ 12-months
Bioresorable Scaffolds - Clinical Studies
*Other ABSORB studies discussed in following slide

4. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
4
2011 2012 2013 2014 2015 2016
ABSORB
PHYSIOLOGY N = ~35
ABSORB IV
N = ~3000
ABSORB Japan
N = 500
ABSORB Cohort A
N = 30; FIM
ABSORB Cohort B
N = 101; FIM
ABSORB III
N = ~2,200
ABSORB China
N = ~400
ABSORB Extend
N = ~1,000
ABSORB II
N = ~500
5Y
1Y 2Y 3Y 4Y 5Y
2Y
2Y
2Y 3Y
2Y 3Y1Y
1Y
1Y
1Y
Enrollment & Follow-Up
Enrollment & Follow-Up
Enrollment & Follow-Up
Enrollment & Follow-Up
Enrollment & Follow-Up
Enrollment/Study Close
Enrollment & Follow-Up
ABSORB First
Multi Country Trial
In Planning
In Planning
Post approval
registries focused
First Time, Young
and Diabetics
APPROVALTHERAPYADVANCEMENT
ABSORB Diabetics
Multi Country Trial
Regional & National Therapy
Demonstration Projects
UK, Sweden, and France
In Planning
Data on file at Abbott Vascular
ABSORB Clinical Trial Program

5. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
5
Absorb Bioresorbable Vascular Scaffold System
Components
Bioresorbable
Coating
• Poly (D,L-lactide)
(PDLLA)
• Naturally
absorbed, fully
metabolized
• Similar dose
density and
release rate to
XIENCE V
Everolimus
• Poly (L-lactide)
(PLLA)
• Naturally
absorbed, fully
metabolized
Bioresorbable
Scaffold
XIENCE V Delivery
System
• World-class
deliverability
All illustrations are artists’ renditions

6. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
6
Porcine Coronary Study:
Representative Photomicrographs (2x)
Absorb
CYPHER
Photos taken by and on file at Abbott Vascular.
2 years1 month 6 months 1 year 3 years
1 month 6 months 1 year 2 years 3 years
4 years
4 years
Tests performed by and data on file at Abbott Vascular.
Absorb vs. CYPHER

7. Porcine Coronary Study: Representative Photomicrographs
Onuma Y, Serruys PW, Perkins LEL, Okamura T, Gonzalo N, Garcia-Garcia HM, et al. Intracoronary optical coherence tomography and histology at 1 month
and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model. An attempt to decipher the
human optical coherence tomography images in the ABSORB trial. Circ 2010;122:1912-1924.
Abbott Vascular Everolimus-Eluting
Bioresorbable Vascular Scaffold

8. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
8
• Lower MCUSA (maximum
unsupported scaffold area)
• More even support of arterial
wall
• More uniform strut distribution
• Lower late stent area loss
• Improved stent retention
• Unchanged material and strut
thickness
Onuma Y, Piazza N, Ormison JA, Serruys PW. Everolimus-eluting bioarbsorbable stent - Abbott Vascular programme. Euroint 2009;5(suppl F):F98-
F102. 009;373:897-910.
Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, et al. A comparative assessment by optical coherence tomography of the
performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2010.
ABSORB Cohorts A & B

9. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
9
Gomez-Lara J, Brugaletta S, Diletti R, Garg S, Onuma Y, Gogas BD, et al. A comparative assessment by optical coherence tomography of the
performance of the first and second generation of the everolimus-eluting bioresorbable vascular scaffolds. Eur Heart J 2010.
COHORT A COHORT B
ABSORB Cohorts A & B
Post-
procedure
6-months Post-
procedure
6-months

10. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
10
A
B
C
D
E
A B C D E
Post-procedure
Pre-procedure

11. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
11
A’
B’
C’
D’ E’
A’ B’ C’ D’ E’

12. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
12
QCA Results at 6 and 12 Months
Serruys, PW. ACC 2011Serruys, PW. AHA 2010
Late Loss at 6 Months (Group 1, N = 45) 12 Months (Group 2, N = 56)
-0.5 0.5 1.5
BMS: 0.85 ± 0.36 mm (N = 27, SPIRIT First)
BVS Cohort A: 0.44 ± 0.35 mm (N = 26)
BVS Cohort B: 0.19 ± 0.18 mm (N = 42, ITT)
EES: 0.10 ± 0.23 mm (N = 22, SPIRIT First)

13. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
13
ABSORB Cohort B to 2 Years:
Comparable Rates with XIENCE
0 194 393 758
Absorb BVS(B1+B2) At Risk 101 96 94 91
XV(3.0 x 18 mm subgroup, SPI+SPII+SPIII RCT) At
Risk
227 219 204 191
ABSORB EXTEND
April 2012
KM estimate of MACE rate in patients treated with Absorb BVS (ABSORB Cohort B, n=101)
vs. patients treated with a single 3x 18 mm metallic XIENCE V (SPIRIT First+II+III, n=227)
Absorb BVS(B1+B2)
XIENCE V (3.0 x 18mm subgroup,SPI+SPII+SPIII RCT)

14. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
14
ABSORB BTK Trial
Treatment of single de novo lesion in BTK vessel, length < 48 mm, in 90
patients with critical limb ischemia (CLI)
• Prospective, Single Arm, Multi-Center Trial in Europe and Asia-Pacific
• Absorb BVS sizes: 3.0 x 18 mm, 3.0 x 28 mm
• Single target lesion treated with Absorb BVS or planned overlap of two Absorb BVS
• Treatment of one or more non-target lesion(s) in separate vessel(s) allowed with
commercial device(s)
Study Objective:
Primary Endpoint:
First-in-Man Study, safety and performance of the Absorb BVS in subjects with CLI
from occlusive vascular disease of the tibial arteries
Freedom from major adverse limb events (major amputation or major reinterventions)
occurring within one year or peri-procedural (30-day) death (MALE+POD)
Secondary Endpoints: Procedural, clinical, hemodynamic, angiographic and functional endpoints in
hospital & at each FU visit
Baseline 1mo 6mo 12mo 2yr 3yr
MSCT/ MR Substudies (N ~ 5 each)
OCT Substudy (N ~ 10)
Angiography (all subjects)
Clinical, Duplex (all subjects)

15. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
15
First Case of Drug-Eluting Resorbable Scaffold Implantation
in the Peripheral Vasculature: ABSORB BTK
Peroneal
Artery
Stenosis
ABSORB
Everolimus-eluting
Resorbable Scaffold

16. Information contained herein for presentation outside the US and outside Japan ONLY. Absorb is authorized
for sale in CE Mark countries. Please check the regulatory status of the device before distribution in areas
where CE marking is not the regulation in force. Not to be reproduced, distributed or excerpted. Absorb is
not approved or available for sale in Mexico.©2012 Abbott. All rights reserved. AP2937175-OUS Rev. A
16
Absorb, ESPRIT, XIENCE PRIME and XIENCE V are trademarks of the Abbott Group of Companies.
Cypher is a trademark of Johnson & Johnson, Inc